NEW YORK – Twist Bioscience and BGI subsidiary MGI International Sales have signed a comarketing agreement for Twist's sequencing target enrichment products in Europe and Asia Pacific, Twist said today.
Under the terms of the non-exclusive agreement, the firms will make Twist's portfolio of NGS target enrichment kits available on MGI's sequencing platforms, including the Twist Human Core Exome, Twist Mouse Exome, Twist RefSeq, Twist Universal Blockers, Twist Fast Hybridization and Wash kits, and Twist's custom panels.
Financial and other terms of the deal were not disclosed.
"This agreement brings together our best-in-class target enrichment products and MGI's high quality, cost-effective, PCR-free sequencing solution, creating a combined platform to embrace the rapidly expanding markets in Asia Pacific and Europe," Twist CEO and Cofounder Emily Leproust said in a statement. "It supports the expansion of our geographic footprint and brings premium target enrichment products to MGI’s customer base, allowing them to experience exceptional enrichment uniformity, custom panel enablement, and optimal performance."
Twist launched its sample preparation kits for NGS in 2018, expanding its offerings beyond gene synthesis. The San Francisco-based firm has courted the Asian market, having signed distribution deals in 2018 covering its NGS products for Japan, Korea, India, and Hong Kong and Macau. In December 2018, Twist also announced it would open a manufacturing facility in China to grow its business in the region.
"Demand is growing for our DNBSeq platform with its high accuracy, affordability, and applications within the marketplace," MGI President Duncan Yu said in a statement. "We look forward to a continued expansion of our offerings with leading products like the Twist target enrichment solution specifically formatted for our platform."